Greetings and welcome to Movano Health Q2 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Jay Cogan, Chief Financial Officer. Thank you, Mr. Cogan. You may begin.

Thanks, Operator. Good afternoon, everyone, and thank you for joining us today. Movano Health’s CEO John Mastrototaro will open today's call with prepared remarks about the progress the company has made during the second quarter of 2024 and in recent weeks. Our CMO, Tyla Bucher, will provide some remarks on the company's upcoming B2C plans, followed again by John, and then I'll provide highlights on the company's quarterly operating results and current financial position. Then we'll open the call for Q&A. John, Tyla, and I will be joined by our Chief Technology Officer and Founder, Michael Leabman, Chief Commercial Officer, Michael Soule, and Vice President of Product and Strategy, Stacy Salvi. Movano Health issued a news release this afternoon detailing second quarter 2024 financial results. Before we begin, I'd like to remind everyone that the company will make forward-looking statements during today's call based on current expectations. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties, and actual results may be materially different from such statements. These risks and uncertainties are detailed in the risk factors section of Movano Health's filings with the Securities and Exchange Commission, specifically in the company's Forms 10-Q and 10-K. Except as otherwise required by federal securities laws, Movano Health disclaims any obligation to update or make revisions to such forward-looking statements contained herein or elsewhere to reflect changes in expectations with regards to those events, conditions, and circumstances. With that, I'll turn the call over to our CEO, John Mastrototaro.

Good afternoon, everyone. Since we last reported earnings in May, we have been working diligently to prioritize the efficient use of our recent capital infusion while continuing to make progress on our key business initiatives as follows: preparing for the expansion of the direct-to-consumer launch at Evie Ring and taking orders again starting September 17; continuing to work with the FDA to secure a 510(k) clearance for the EV Med Ring; delivering our first B2B commercial opportunities with healthcare partners; and lastly, preparing for upcoming blood pressure and glucose clinical trials using the most recent iteration of our wearable device that incorporates our proprietary RF solution. We continue to be judicious with our capital and methodical in our approach to building out our direct-to-consumer and business-to-business market opportunities. I will provide an update on our progress with the FDA and preparations for the B2B launch at EV Med. We are working closely with the FDA to secure a 510(k) clearance in preparation for the launch of EV Med. As we highlighted in a press release last week, we plan to meet with the FDA this month. You'll recall the EV Med Ring is designed to not only provide medical device functionality with its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity, and logging of mood, energy, and health symptoms. Subsequent to our April 510(k) filing, in May and early June, the FDA review team requested two minor clarifications, and our team promptly responded. In late June, the FDA review team requested some additional information related to the wellness aspects of EV Med. Along with our regulatory advisors, Movano Health provided a draft response to the FDA's questions on July 10 and requested a meeting with the agency to review our draft response, which is now scheduled, as I noted earlier. We look forward to meeting with the FDA and working toward resolving this issue in order to move forward with the review process. We remain steadfast in our commitment to the opportunity EV Med could unlock, given the clinical evidence provided as part of the filing related to the pulse oximetry feature and our desire to work collaboratively with the agency. Regarding the EV Med opportunity, we have three new B2B commercial opportunities to highlight for you today. In anticipation of an expected 510(k) clearance, we are engaged with two global pharmaceutical companies that could leverage EV Med in building unique solutions for both clinical and consumer applications. In the first case, we are in the agreement phase for a program that could begin in late 2024 and, assuming success, would be expected to develop into a larger commercial opportunity in 2025. In the second case, EV Med is expected to be evaluated this fall by a Tier 1 global pharmaceutical company for a clinical trial that is scheduled to commence in 2025. We are also engaged with a large payer looking to better manage high-risk populations utilizing EV Med. This opportunity is expected to kick off around the New Year and, assuming a positive outcome, the commercial opportunity could build into 2025. All three of these strategic partners, as well as the others in our funnel, see EV Med as a game-changing solution that is not currently available in the market. This is in addition to our recent announcement of the partnership with the Tal Research Group at MIT to use EV Ring for its MAESTRO clinical study on the long-term health impacts of Lyme disease and long COVID. To explain these health care opportunities in more depth, we recently hosted our first virtual event titled B2B, The Next Wearables Boom, where Managing Director of Allele Capital, Matt Hughes, moderated a panel that included myself, our Chief Commercial Officer, Michael Soule; and Stanford Cardiologist, Doctor Fatima Rodriguez. During the event, we identified and discussed the significant B2B possibilities that could be unlocked specifically for clinical trials and remote patient monitoring following a 510(k) clearance. As you'll recall, the clinical trials market we seek to address consists of pharmaceutical companies that need to gather data from FDA-cleared devices as part of their drug trials for FDA and other regulatory submissions. We've identified the TAM for FDA-cleared wearables in this market to be as much as 5 billion annually. Currently, trials are offering cumbersome, expensive, and suboptimal requiring in-person checkups, which can result in poor compliance. We believe EV Med's unique offering and design aesthetic would improve compliance, lower costs significantly, and enable quicker enrollment, better data, and improved quality of results. The three examples I highlighted a few minutes ago speak to this need, and we are aggressively pursuing opportunities across clinical trials and post-market surveillance. For Remote Patient Monitoring or RPM, the market barely existed four years ago. However, COVID unlocked the reality that RPM can reduce the need for in-office visits, expand access, and reduce costs. We believe EV Med will be able to automate the collection of more complete and accurate data resulting in an RPM solution with meaningful advantages over RPM products on the market today. During our conversation, Doctor Rodriguez also validated the need for RPM in her role as a physician, which would enable her to manage patients in between visits and easily identify patterns. We recently completed beta testing our wearable technology with a leading U.S. RPM company that serves over 450 health care organizations and is the exclusive platform for one of the largest medical device companies in the world. In anticipation of these partnerships and more, we are preparing our back-end operations to meet our partners' requirements, including positioning the company to scale efficiently, establishing app and labeling modifications to support a medical device, and building our API and data sharing framework. I will now turn it over to our CMO, Tyla Bucher, to provide an update on our D2C plans for the Evie Ring.

Thanks, John. As you all know, we've been out of stock on the Evie Ring since Q1, and we've been using this time to implement a series of improvements for our existing and prospective customers, including operational and delivery timelines, better and more accurate ring functionality, best-in-class customer service, and finalizing some new and necessary features. From an operations standpoint, we improved production yields and cycle times, as well as our logistics and warehouse management system. This will result in greater efficiency on the production floor and allow us to keep a more accurate real-time track of inventory and the flow of orders. From a software perspective, we updated our Ring algorithms, improving accuracy across sleep and wake times, sleep stages, heart rate measurement during activity, and steps. In addition, we expanded our proprietary AI-generated insights engine to include hundreds of new insights for our users, customized for individual wellness journeys and informed by a combination of track and log data. An example of one of our newer insights would be, when you beat your average step by more than 1,000, you tend to report a better mood. Regarding customer service, we built out a new team of representatives with a combined 25-plus years of service in the direct-to-consumer space, who have a solid understanding of the pace and real-time knowledge delivery that a product like ours requires. This team is currently responding live to all inquiries within 48 hours and has drafted a comprehensive library of useful articles, tips, and tricks that can be shared with Evie Ring consumers as they work through any issues together, or the customers can use it if they prefer. In addition, these articles feed into our AI-powered chatbot that can mitigate many easily solvable issues and get smarter as it ingests both the inquiries and our information, responding quickly and accurately to customers in friendly and native language. In addition to all these enhancements, we are also working on an auto activity detect workout feature, which will allow you to understand that you're working out even if you have not started to work out on the app. Following the workout, we'll be able to provide you with your results. Users will also be able to modify the details of their workout after the fact. Finally, we expect to have an Android version of the app ready for our prospective Android users, of which there are quite a few, to purchase by Black Friday in November of this year. We are pleased to announce that we'll be back in stock on September 17, post summer season and time for when consumers begin turning their attention to the holidays and gift-giving. We have a full paid and organic social campaign prepared to support our launch which includes influencer and user-generated content across Instagram, Facebook, YouTube, and TikTok as well as Google Search and Shop. We also have a robust email lead list that has grown exponentially with consumers ready to buy, and we will be engaging them with a comprehensive outreach strategy. We have a satellite press lined up with key tech and consumer press as well as a pitch campaign for holiday gift guides across print and television. Finally, we could not be more excited to share the introduction of our brand partnership with digital creator, wife, mom, and entrepreneur Heidi D'Amelio. Heidi has been using the Evie Ring for several months and has really become a true fan. Aligned with our mission of empowering women with better data and insights to help them live healthier lives, we have formed a strategic partnership with Heidi where we'll continue to grow the brand, drive awareness around women's health, and improve the ring experience together. We couldn't be more excited to welcome Heidi to the Evie family. As you can see, we've been working around the clock to get the ring back in the hands of consumers, and we truly believe it will be worth the wait. With that, I'll turn things back over to John.

Thanks, Tyla. As you are aware, our product development plan extends far beyond Evie and Evie Med. We are deeply invested in multi-analyte sensing and pursuing additional FDA clearances with further research in respiration rate, core temperature, and a solution to address sleep disturbances. Some of these metrics may only require a software update, while others may require new hardware components or potentially different form factors. We are in the planning stages now for several clinical trials related to these valuable analytes. As a follow-on to the successful blood pressure study we conducted in Q4 '23, we completed our most recent blood pressure clinical study in June, which included the use of an arterial blood pressure line. We learned a great deal about improved ways to collect data, and we'll be redesigning for the next study with better placement of the sensors on the body to maximize their utility. We're also in the process of designing a more consumer-friendly form factor as we focus on commercializing the solution. We will continue to develop this into Q4 with another study planned before the year-end. In summary, we remain committed to improving health monitoring through the introduction of additional analyte sensing, including blood pressure and glucose using our millimeter-wave radio frequency and AI technology. With that, I'll now hand the call over to Jay for the financial review.

Thanks, John. We shipped 1,837 Evie Rings in the second quarter of 2024 as we completed fulfillment of our initial launch phase. You'll recall that we shipped approximately 5,300 Rings in the first quarter and stopped taking orders in mid-February due to capital market conditions. The company did not report any revenue for the second quarter as previously deferred revenues offset by refunds. As we noted earlier in the call, we expect to begin taking orders and shipping rings again in September. We plan to have ample inventory prior to taking orders again in September. As Tyla highlighted, we have made important strides across product manufacturing and customer service that should position us well for both an expanded launch of Evie Ring in D2C and the eventual launch of Evie Med in B2B upon an FDA clearance decision. Following our successful capital placement in April, where the company raised $24.1 million in gross proceeds, including a strategic seed investment from a Tier 1 multibillion-dollar medical device company, we recently executed a turnkey agreement with our production partner, which should free up both working capital and human resources for Movano Health going forward. The company reported an operating loss of $6.4 million in the second quarter of 2024 versus an operating loss of $7.4 million in the year-ago period, and we had $16.9 million in cash and cash equivalents on our balance sheet at June 30, which takes into account our catching up on more than $3 million of outstanding payables following the April private placement, putting us in good standing with our partners as we position the company to execute against key future milestones. Excluding the catch-up, our cash burn in the quarter was approximately $4.4 million as managing resources continues to be a priority for the company. Now I'll turn it back over to John for final remarks.

Thanks, Jay. The team and I couldn't be more excited about all of the progress we just highlighted. We are nearing an inflection point for the company as we close in on key Evie and Evie Med milestones. We are laser-focused on the expansion of our D2C business, bullish on the B2B opportunities for Evie Med, and optimistic about the potential of our RF chip. We look forward to continuing to share our progress as we head into the back half of the year. With that, we'd be happy to take your questions.

Thank you. We will now begin the question-and-answer session. The first question comes from Bruce Jackson with Benchmark Company. Please go ahead.

Hi, good afternoon. Thank you for taking my questions. With the new Evie that's going to launch with the auto activity detect features, is that the same thing as the new heart rate and motion algorithm that you just developed?

Michael Leabman, would you like to go ahead and respond to that question from Bruce?

Yeah, sure. I think the first big fix we've added is we've changed our heart rate algorithm to be really based on machine or deep learning to get much more accurate heart rate motion if you're walking, jogging, running, etc. That's a stand-alone algorithm. The auto activity is really twofold. One, to identify what activities you're doing, as well as, as Tyla mentioned, to be able to start collecting data even if you don't tell your watch, your ring, or your app to start collecting. So there are kind of two separate things that combine to give you much better results for a workout.

Okay. Great. And then moving over to the business-to-business side. With the provider organization where you've got an engagement, can you maybe go into a little bit more detail about that as to the depth of the engagement? Is it like on parallel activities? Or do they have any minimum orders attached to the engagement?

Thanks, Bruce. Michael Soule, do you want to go ahead and take that question?

We are currently working with various channels, including providers and payers, as well as remote patient monitoring. In preparation for our FDA approval, they are assisting us in different ways through beta testing. We are also in early discussions with several parties, including providers, payers, and remote patient monitoring channels.

Okay. Great. And then last question for me. Any changes on the mid-August date for meeting with the FDA?

I'll take that one, Bruce. Thanks for the question. No, no changes there. I'd just like to make a couple of comments about it. We still are very optimistic regarding our ability to work with the agency for a few reasons. First off, we've got a pretty seasoned and deep regulatory team in the company itself, but we've gone one step beyond that. In fact, we're also working with the leading regulatory firm in the U.S., and probably the principal of whom has probably had more meetings with the FDA than anyone in their career. So we've really got the top team that we could possibly have working on this to assure that we're complying with all the FDA policies. When you're doing something new with our Ring and we've got the wellness and medical devices in the product, it can raise some new questions of the agency, but we feel really good about where we stand. We've had some recent communications in preparation for the meeting, and it's all trending in the right direction. So that is all positive. One thing we always kind of remember is that the whole filing is built on a really strong foundation of incredibly strong clinical data and results for the pulse oximetry feature. For all of these reasons, we still feel really good about where we are and being able to work through the FDA and gain a clearance.

Okay. Great. Congratulations on all of the progress. And thank you for taking my questions.

Thank you, Bruce.

Thanks, Bruce. Operator, it looks like we have some questions on the webcast. I can go ahead and ask those and we'll see what happens with the phone lines thereafter. John, I guess, if there's anything else, there's a question here about the 510(k) submission. If there's anything else you wanted to add in terms of our confidence in securing it or just anything else beyond the press release that we issued last week, if there's anything to discuss otherwise, we can move on to the next question.

Yeah, I saw that question. I saw that question online, and I tried to answer it at the same time that I answered Bruce. So I think that covered it pretty well. Bottom line is we still feel really confident and optimistic in where we stand and are very much looking forward to meeting with the agency soon to resolve this and move on to the next topic.

Okay, great. The next couple of questions can be for Tyla. Tyla, there's a couple of questions about the press and marketing plan for the expanded launch of Evie Ring? And then also, what are the biggest changes that we've made to the ring and app heading into this expanded launch?

Sure. So I think as I noted on the call, we've obviously spent the last few months focusing on improvements across the board, including updating and fine-tuning the algorithms. I think the big focus has also been on our insights engine because really that is a key differentiator for us. The other pieces are the auto activity detect that Bruce just mentioned as well as an Android version of the app. Both of these are key features that consumers have been asking for. We want our community to know that we're listening, and we're excited to roll out these enhancements. In terms of marketing, we have a full campaign ready to go that includes influencer and user-generated content across Instagram, Facebook, YouTube, and all the other platforms I mentioned, as well as Google Search and Shop. We have a really engaged lead list and a comprehensive outreach strategy. Above and beyond, we're thrilled with the announcement of our partnership with influencer and digital creator, Heidi D'Amelio. Not only does she have a passion for fitness, but she has a highly engaged audience, and she shares the vision of improving women's health with better data and insights. We will work closely with someone like Heidi to drive awareness around the Evie Ring and the importance of a wellness device for women, which is a significant step forward for us.

Great. All right. Michael Soule, you might have answered some of this or most of this in the prior question from Bruce. But a question on the webcast relates to taking a deeper dive into the first Evie Med commercial opportunities that we've announced recently and how they position the company for growth with pharma and other health partners in the future.

Yeah. Sure. Yeah. And I saw that as well online. I think in the last call, we talked a little bit about our data partners, right? We've run the gamut across various channels with our beta partners. Since coming out of that data phase, other large strategic partners have come to us looking to work with us. They range from medical device to pharma, to payers who are looking forward to our FDA clearance. When that clearance comes, we expect to unlock a host of initiatives across clinical trials and remote patient monitoring. We are also, as John mentioned earlier, building the back-end systems required for these partnerships so we can hit the ground running. In advance of that clearance, we've moved into agreement discussions with several folks, and we're very excited about the pace with which this is happening.

Perfect. Next question for Michael Leabman. What did you learn in your most recent blood pressure clinical study?

Yeah. Great. So I think as John mentioned, we concluded our study in June, and we've been analyzing the data using arterial line, which is really new to us giving us continuous data. It has allowed us to fine-tune our device, including new antennas that we've already completed designing as well as accommodating different risk sizes with a smaller form factor, getting us closer to commercialization. All these changes will allow us to begin testing with B2B customers when we're ready, and the expected new design will arrive somewhere at the end of September, early October as we prepare for our next clinical arterial line study in November. I think everything is coming together nicely from this first study, and we're excited to get this hardware back and take the next step.

Okay. Thanks, Michael. John and Tyla, there's a question about the company taking the path of being a medical device company and with blood pressure and glucose on the horizon, is Movano planning to expand its marketing to target beyond women?

Yeah. From the Med Device perspective, I'll take that aspect. Certainly, as you're aware and alluded to for direct-to-consumer, we have had a female focus and Tyla can expand upon that in a moment. But for the opportunities we have in the health care space, there are products that are specific for women. This dovetails nicely, but many of the opportunities we're looking at are for anyone. Just because we've targeted women with some aspects of the app experience and design does not mean that it's not of tremendous value for everyone. All of our partners agree that this will suit all of our customers or subscribers to a plan or whatever it may be. They're looking at using it universally. Importantly, whether it's continuous glucose monitoring in the future or blood pressure and what we have today with heart rate, Sp02, and other future analytes, they are essential for everyone. Half the population over age 20 in the U.S. has high blood pressure or is pre-hypertensive, and diabetes affects about a third of the people. Products like this that can be worn and used at home in a user-friendly way are crucial to bring health care into the home. We are more aware of our health than ever before after COVID and the like. This represents a massive opportunity, and we are engaging leaders in the health care space about products that can seamlessly support the health and wellness of people. Tyla, do you have anything to add specifically about the D2C and the female focus there?

Sure. I mean I think you captured it well. The only comment that I would make is to echo your notes about we didn't design the Evie Ring to the exclusion of the male gender, but rather to really be present for women who prioritize their health prior to the health of their family. Women control the pulse strings, make decisions for the family, and we wanted to provide a solution for them to prioritize their wellness. You can wear the Evie Ring regardless of gender. We considered how women would like to receive the data, how they want to see it displayed in their app, a comfortable fit, and ensure that we're delivering insights that make them feel this is a worthwhile endeavor and that they understand what to do with that data. We see a tremendous opportunity among women, but anyone can wear the ring. It will still work, and it will track your health and well-being.

Thanks, Tyla and John. I'll take the last question. It looks like you've made some good progress on reducing your quarterly burn rates. How do we see the trend in our expanded launch of Evie Ring and eventually Evie Med?

We appreciate the feedback. We continue to be focused as an organization on the highest and best use of our capital and the margin profile of the D2C and B2B businesses that we're rolling out. We believe the product manufacturing and customer service improvements that we've implemented over the past few months should help position us for growth and cash flow. The turnkey agreement, which we've now executed with our contract manufacturing partner, will improve our cash flow profile, better aligning sales and the actual cost of goods. Operator, I'm saying in closing, if investors would like to stay up to date on Movano Health, please continue to check into ir.movano.com. We look forward to staying in touch, and we will see you next quarter. Thank you for your support.

Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.